Chronic myeloid leukemia (CML) cancer cells, resistant to imatinib, express higher levels of Nrf2 and TrxR, involved in protecting cancer cells from the harmful effects of the drug (Xu et al., 2019). This evidence concerns the gene NFE2L2 and chronic myelogenous leukemia, BCR-ABL1 positive.